



## Pharmacogenomics - A Genetic Approach to Drug Therapy and Development

Guest Editor:

### Dr. Mohammad Mobashir

1. Department of Biomedical Laboratory Science, Faculty of Natural Sciences, Norwegian University of Science and Technology, NO-7491 Trondheim, Norway

2. Department of Microbiology, Tumor and Cell Biology (MTC) Karolinska Institute, Nobels väg 16, Solna, 17165 Stockholm, Sweden

3. SciLifeLab, Department of Oncology and Pathology, Karolinska Institutet, P.O. Box 1031, 17121 Stockholm, Sweden

Deadline for manuscript submissions:

**closed (31 March 2024)**

### Message from the Guest Editor

Dear Colleagues,

Drug interactions are better understood with the application of pharmacogenomics, the most well-known study now used in medical sciences. Regarding therapies and drug development, it has a significant impact. The large-scale implementation of pharmacogenomics is required in the area of therapeutic development. The main focus is on how genes and a complex gene system affect how the body reacts to medications. According to the most recent developments in the field of clinical therapeutics, new biomarkers have been identified that make it simpler to identify a group of patients who are more or less likely to respond to specific treatments. A combination of genetic, environmental, and patient features that have an impact on the pharmacokinetics and/or pharmacodynamics of medications results in inter-individual variance in drug response.

With this Special Issue, we aim to present research/review articles, commentaries, etc. that could serve as potential sources of new application/methodology/approach implementation in the field of pharmacogenomics. The topics of this Special Issue may be experimental or theoretical.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e  
Bioquímica (DQB) e Centro de  
Química Estrutural (CQE),  
Institute of Molecular Sciences,  
Faculdade de Ciências,  
Universidade de Lisboa, Lisboa,  
Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)